Boston Scientific Corporation (Jobs) Gets Warning Letter
Published: Sep 10, 2007
NEW YORK - Leerink Swann & Co. reaffirmed a "Market Perform" rating for Boston Scientific Corp. Monday, despite the company receiving a warning letter from the Food and Drug Administration for not disclosing deaths in a now canceled drug development program. On Friday, the FDA's warning letter chided Boston Scientific for failing to report two of five deaths in a 43-patient stent trial aimed at treating abdominal aortic aneurysms. The study was abandoned in 2006 after learning that the device had serious problems that resulted in at least 25 stent fractures.